Discussion
Marvel Biosciences’ lead experimental oral therapy MB-204 moved multiple measures of behavior and cognitive function toward normal levels in a mouse model of fragile X syndrome (FXS), with some signs of a potential carry-over effect after treatment was discontinued. “This is now the third ASD [autism spectrum disorder]…